mdm 2 mRNA expression is associated with survival in ovarian cancer

International Journal of Cancer

Volumn 74, Issue 4, 1997, Pages 438-442

  Tanner, Berno ^a   Hengstler, Jan Georg ^a   Laubscher, Silke ^a   Meinert, Rolf ^a   Oesch, Franz ^a   Weikel, Wolfgang ^a   Knapstein, Paul Georg ^a   Becker, Roger ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; MESSENGER RNA; PROTEIN P53;

ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; OVARY CANCER; PRIORITY JOURNAL; PROGNOSIS; TUMOR SUPPRESSOR GENE;

CONFIDENCE INTERVALS; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYSTERECTOMY; NEOPLASM PROTEINS; NEOPLASM STAGING; NUCLEAR PROTEINS; OMENTUM; OVARIAN NEOPLASMS; OVARIECTOMY; PREDICTIVE VALUE OF TESTS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; RECURRENCE; RISK ASSESSMENT; RNA PROBES; RNA, MESSENGER; SURVIVAL RATE; TRANSCRIPTION, GENETIC;

EID: 0030828285     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19970822)74:4<438::AID-IJC13>3.0.CO;2-5     Document Type: Article

References (28)

1. BRACHMAN, D.G., BECKETT, M., GRAVES, D., HARAF, D., VOKES, E. and WEICHSELBAUM, R.R., p53 mutation does not correlate with radiosensitivity in 24 head-and-neck-cancer cell lines. Cancer Res., 53, 3666-3660 (1993).
2. BROWN, R., CLUGSTON, C., BURNS, P., EDLIN, A., VASEY, P., VOJTESEK, B. and KAYE, S.B., Increased accumulation of p53 protein in cisplatin-resistant ovarian cell lines. Int. J. Cancer, 55, 678-684 (1993).
3. CHOMCZYNSKI, P. and SACCHI, N., Single-step method of RNA isolation by acid-guanidinium-thiocyanate-phenol-chloroform extraction. Anal. Biochem., 162, 156-159 (1987).
4. CLARKE, A.R., PURDIE, C.A., HARRISON, D.J., MORRIS, R.G,. BIRD, C.C., HOOPER, M.L. and WYLLIE, A.H., Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature (Lond.), 362, 847-849 (1993).
5. CZERNOBILSKY, B., Common epithelial tumors of the ovary. In: R.J. Kurman, (ed.), Blaustein's pathology of the female genital tract, pp. 560-607, Springer, New York, (1987).
6. ELIOPOULOS, A.G., KERR, D.J., HEROD, J., HODGKINS, L., KRAJEWSKI, S., REED, J.C. and YOUNG, L.S., The control of apoptosis and drug resistance in ovarian cancer: influence of p53 and Bcl-2. Oncogene, 11, 1217-1228 (1995).
7. FAKHARZADEH, S.S., TRUSKO, S.P. and GEORGE, D.L., Tumorigenic potential associated with enhanced expression of a gene that is amplified in a mouse tumor cell line. EMBO J, 10, 1565-1568 (1991).
8. FAN, S., EL-DEIRY, W.S., BAE, I., FREEMAN, J., JONDIE, D., BHATIA, K., FURNACE, A.J. JR., MAGRATH, I., KOHN, K.W. and O'CONNOR, P.M., p53 gene mutations are associated with decreased sensitivity of human lymphoma cells to DNA-damaging agents. Cancer Res., 54, 5824-5830 (1994).
9. FAN, S., SMITH, M.L., RIVET II, D.J., DUBA, D., ZHAN, Q., KOHN, K.W., FORNACE, A.J. JR. and O'CONNOR, P.M., Disruption of p53 function sensitizes breast cancer MCF cells to cisplatin and pentoxifylline. Cancer Res., 55, 1649-1654 (1995).
10. FINLAY, C.A., The mdm-2 oncogene can overcome wild-type-p53 suppression of transformed cell growth. Mol. cell. Biol., 123, 301-306 (1993).
11. FOULKES, W.D., STAMP, G.W.H., AFZAL, S., LALANI, N., McFARLANE, C.P., TROWSDALE, J. and CAMPBELL, I.G., MDM2 over-expression is rare in ovarian carcinoma irrespective of TP53 mutation status. Brit. J. Cancer, 72, 883-888 (1995).
12. GJERSET, R.A., TURLA, S.T., SOBOL, R.E., SCALISE, J.J., MERCOLA, D., COLLINS, H. and HOPKINS, P.J., Use of wild-type p53 to achieve complete treatment sensitization of tumor cells expressing endogenous mutant p53. Mol. Carcinog. 14, 275-285 (1995).
13. KALBFLEISCH, J.D. and PRENTICE, R.C., The statistical analysis of failure time data. Wiley, New York (1980).
14. KONDO, S., BARNETT, G.H., HARA, H., MORIMURA, T. and TAKEUCHI, J., MDM-2 protein confers the resistance of a human glioblastoma cell line to cisplatin-induced apoptosis. Oncogene, 10, 2001-2006 (1995).
15. KRIEG, P.A. and MELTON, D.A., Functional messenger RNAs are produced by SP6 transcription of cloned cDNAs. Nucleic Acids Res., 12, 7057-7070 (1984).
16. KUERBITZ, S.J., PLUNKETT, B.S., WALSH, W.V. and KASTAN, M.B., Wild-type p53 is a cell-cycle checkpoint determinant following irradiation. Proc. nat. Acad. Sci. (Wash.), 89, 7491-7495 (1992).
17. LANE, D.P., Cancer. p53, guardian of the genome. Nature (Lond.), 358, 15-16 (1992).
18. LOWE, S.W., RULEY, H.E., JACKS, T. and HOUSEMAN, D.E., p53-dependent apoptosis modulates the cytotoxicity of anti-cancer agents. Cell, 74, 957-967 (1993a).
19. LOWE, S.W., SCHMITT, E.M., SMITH, S.W., OSBORNE, B.A. and JACKS, T., p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature (Lond.). 362, 849-852 (1993b).
20. MELTZER, P.S., MDM2 and p53: a question of balance. J. nat. Cancer Inst., 86, 1265-1266 (1994).
21. MYERS, R.M., LARIN, Z. and MANIATIS, T., Detection of single-base substitutions by ribonuclease cleavage at mismatches in RNA:DNA duplexes. Science, 230, 1242-1246 (1985).
22. O'CONNOR, P.M. and KOHN, K.W., A fundamental role for cell-cycle regulation in the chemosensitivity of cancer cells. Semin. Cancer Biol., 3, 309-416 (1992).
23. OLINER, J.D., PIETENPOL, J.A., THIAGALINGHAM, S., GYURIS, J., KINZLER, K.W. and VOGELSTEIN, B., Oncoprotein MDM2 conceals the activation domain of tumour-suppressor p53. Nature (Lond.), 362, 857-860 (1993).
24. RIVA-LAVIEILLE, C., Drug resistance, oncogenes and anti-oncogenes in epithelial tumors. Bull. Cancer (Paris). 81, 105-111 (1994).
25. SMITH, M.L., CHEN, I., ZHAN, Q., BAE, I., CHEN, C., GILMER, T., KASTAN, M.B., O'CONNOR, P.M. and FURNACE, A.J. JR., Interaction of the p53-regulated protein Gadd45 with proliferating-cell nuclear antigen. Science, 266, 1376-1380 (1994).
26. 1 checkpoint does not decrease cell survival following DNA damage. Cancer Res., 53, 4164-4168 (1993).
27. TANNER, B., FRIEDBERG, T., MITZE, M., BECK, T., OESCH, F. and KNAPSTEIN, P.G., C-erbB-2-oncogene expression in breast carcinoma: analysis by S1-nuclease-protection assay and immunohistochemistry in relation to clinical parameters. Gynecol Oncol., 47, 228-233 (1992).
28. WORLD HEALTH ORGANIZATION, International Classification of Tumours, 9, WHO, Geneva (1973).